pacDNA is a seed-stage company aiming to transform the field of gene regulation therapeutics with our Brushield™ oligonucleotide delivery technology, which addresses several pain points in one simple but potent molecular construct. The Brushield™ platform can rapidly generate potent clinical leads with fewer side effects at a lower dosage, delivered to non-liver sites such as muscle, GI tract, and skin. Our lead program in myotonic dystrophy type 1 (DM1) shows superior delivery to skeletal muscles compared to leading clinical candidate, and shows potent splicing correction. The technology is protected by seven PCT/US patent applications (foundational patent has been granted).